Contents

Reviews

Neurofibromatosis Type 2 Protein, NF2: An Uncoventional Cell Cycle Regulator. S. BELTRAMI, R. KIM, J. GORDON (Philadelphia, PA, USA) ............................................................... 1

Anticancer Efficacy of the Metabolic Blocker 3-Bromopyruvate: Specific Molecular Targeting. S. GANAPATHY-KANNIAPPAN, R. KUNJITHAPATHAM, J.-F. GESCHWIND (Baltimore, MD, USA) ............ 13

The Mammalian Target of Rapamycin Inhibitors in Breast Cancer: Current Evidence and Future Directions. P. MALAGUTI, S. VARI, F. COGNETTI, A. FABI (Rome, Italy) ........................................... 21


Genistein and Daidzein: Different Molecular Effects on Prostate Cancer. M. ADJAKLY, M. NGOLLO, J.-P. BOITEUX, Y.-J. BIGNON, L. GUY, D. BERNARD-GALLON (Clermont-Ferrand, France) ............. 39

Experimental Studies

Silencing of the ARP2/3 Complex Disturbs Pancreatic Cancer Cell Migration. H.E. RAUHALA, S. TEPO, S. NIEMELÄ, A. KALLIONIEMI (Tampere, Finland) .................................................. 45

LAT52 Is a Modulator of Estrogen Receptor Alpha. L.C. LIT, S. SCOTT, H. ZHANG, J. STEBBING, A. PHOTIOU, G. GIAMAS (London, UK) ................................................................. 53

Contents continued on the back cover
Editorial Board

B. B. Aggarwal  
Cytokine Research Laboratory, Department of Experimental Therapeutics, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA

A. Arigiris  
Division of Hematology/Oncology, UT Health Science Center at San Antonio, San Antonio, TX, USA

J. P. Armand  
Institut Claudius Regaud, Toulouse, France

V. I. Avramis  
Division of Hematology/Oncology, Childrens Hospital, Los Angeles, CA, USA

R. C. Bast  
Department of Translational Research, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA

G. Bauer  
Abteilung Virologie, Institut für Medizinische Mikrobiologie und Hygiene, Universität Freiburg, Germany

E. E. Baulieu  
INSERM U488 and College de France, Le Kremlin-Bicetre, France

Y. Becker  
Department of Biochemistry, Faculty of Medicine, Hebrew University of Jerusalem, Ein Kerem, Jerusalem, Israel

E. J. Benz, Jr.  
Dana-Farber Cancer Institute, Boston, MA, USA

J. Bergh  
Department of Clinical and Molecular Medicine, Radiumhemmet, Karolinska Institute, Stockholm, Sweden

D. D. Bigner  
Department of Pathology, Duke University Medical Center, Durham, NC, USA

A. Böcking  
Institute for Cytopathology, University of Düsseldorf, Germany

G. Bonadonna  
Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy

F. T. Bosman  
Institute of Pathology, University of Lausanne, Switzerland

G. Broich  
Gruppo Policlinico di Monza, Monza, Italy

J. M. Brown  
Department of Radiation Oncology, Stanford Medical Center, Stanford, CA, USA

O. S. Bruland  
Department of Medical Oncology-Radiotherapy, Norwegian Radium Hospital, Oslo, Norway

M. M. Burger  
Novartis, Basel, Switzerland

M. Carbone  
Cancer Research Center of Hawaii, Honolulu, HI, USA

J. Carlsson  
Department of Biomedical Radiation Sciences, Uppsala University, Sweden

A. F. Chambers  
Department of Oncology, London Regional Cancer Center, London, Ontario, Canada

P. Chandra  
Abt. für Molekularbiologie, Klinikum Wolfgang Goethe-Universität, Frankfurt am Main, Germany

L. Cheng  
Department of Pathology, Indiana University School of Medicine, Indianapolis, IN, USA

J.-G. Chung  
Department of Biological Science and Technology, China Medical University, Taichung, Taiwan, ROC

E. De Clercq  
Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium

W. De Loecker  
Department of Biochemistry, Katholieke Universiteit Leuven, Belgium

W. Den Otter  
VUMC, Department of Urology, Amsterdam, The Netherlands

E. P. Diamandis  
Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada

G. Th. Diamandopoulos  
Department of Pathology, Harvard Medical School, Boston, MA, USA

W. Ebert  
Thoraxclinic HD-Rohrbach, Heidelberg, Germany

D.W. Felsher  
Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA

J. A. Fernandez-Pol  
Metalloproteomics, LLC, Chesterfield, MO, USA

I. J. Fidler  
Department of Cancer Biology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA

A.P. Fields  
Department of Cancer Biology, College of Medicine, Mayo Clinic, Jacksonville, FL, USA

G. Gabbiani  
Department of Pathology, University of Geneva, Switzerland

R. Ganapathi  
Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC, USA

A. F. Gazdar  
Hamon Center for Therapeutic Oncology Research, University of Texas Southeastern Medical Center, Dallas, TX, USA

J.H. Geschwind  
Interventional Radiology Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA

A. Giordano  
Sbarro Institute for Cancer Research, Temple University, Philadelphia, PA, USA

G. Gitsch  
Department of Gynecology and Obstetrics, University of Freiburg, Germany

R. H. Goldfarb  
Sopherion Therapeutics, Inc., Princeton, NJ, USA

J. W. Gorrod  
Toxicology Unit, John Tabor Laboratories, University of Essex, Colchester, Essex, UK

S. Hammarström  
Department of Immunology, University of Umeå, Sweden

I. Hart  
Centre for Tumour Biology, Institute of Cancer and CR-UK Clinical Centre, Bart’s and The London, Queen Mary’s School of Medicine and Dentistry, London, UK

continued
I. Hellström
Harborview Medical Center, Seattle, WA, USA

L. Helson
Sign Path Pharma, Inc., Quakertown, PA, USA

R. B. Herberman
Intrexon Corporation, Germantown, MD, USA

R. M. Hoffman
Department of Surgery, University of California, San Diego, CA, USA

C. G. Ioannides
Department of Gynecology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA

K.-S. Jeong
Department of Pathology, College of Veterinary Medicine, Kyungpook National University, Daegu, South Korea

S. C. Jhanwar
Laboratory of Solid Tumor Genetics, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

J. V. Johannessen
Department of Pathology, The Norwegian Radium Hospital, Oslo, Norway

B. Kaina
Institute of Toxicology, University of Mainz, Germany

B. K. Keppler
School of Medicine, University of Vienna, Austria

D. G. Kieback
Department of Obstetrics and Gynecology, Elblandklinikum Riesa, Riesa (Dresden), Germany

R. Klapdor
Medical Clinic, University of Hamburg, Germany

U. R. Kleeberg
Hämatologisch - Onkologisch - Praxis Altona, Hamburg, Germany

P. Kleihues
Department of Pathology, University Hospital Zürich, Switzerland

E. Klein
Department of Tumor Biology, Karolinska Institute, Stockholm, Sweden

S. von Kleist
Institut für Immunologie der Universität der Freiburg, Germany

S. D. Kottaridis
Department of Virology, Hellenic Anticancer Institute, Athens, Greece

G. R. F. Krueger
Center of Anatomy II, University of Cologne Medical School, Cologne, Germany

D. W. Kufe
Division of Medicine, Dana-Farber Cancer Institute, Boston, MA, USA

Pat M. Kumar
Department of Biological Sciences, Manchester Metropolitan University, Manchester, UK

Shant Kumar
Department Pathology, University of Manchester Medical School, Manchester, UK

M. Kuroki
Department of Biochemistry, Fukuoka University School of Medicine, Fukuoka, Japan

O. D. Laerum
Department of Pathology, The Gade Institute, University of Bergen, Norway

F. J. Lejeune
Fondation du Centre Pluridisciplinaire d’Oncologie, CHUV, Lausanne, Switzerland

L. F. Liu
Department of Pharmacology, UMD of New Jersey, Piscataway, NJ, USA

D. M. Lopez
Department of Microbiology and Immunology, University of Miami School of Medicine, Miami, FL, USA

E. Lundgren
Unit of Applied Cell and Molecular Biology, University of Umeå, Sweden

H. T. Lynch
Department of Preventive Medicine and Public Health, Creighton University, Omaha, NE, USA

J. Marescaux
IRCAD, University of Strasbourg, France

J. Mark
Department of Pathology, Känsjukhuset, Skövde, Sweden

J. F. Marshall
Centre for Tumour Biology, Institute of Cancer and CR-UK Clinical Centre, Bart’s and The London, Queen Mary’s School of Medicine and Dentistry, London, UK

D. Medina
Department of Cell Biology, Baylor College of Medicine, Houston, TX, USA

S. Mitra
Sealy Center for Molecular Science, University of Texas Medical Branch, Galveston, TX, USA

M. Mueller
Research Group of Tumor and Microenvironment (A101), German Cancer Research Center (DKFZ), Heidelberg, Germany

F. M. Muggia
New York University Cancer Institute, School of Medicine, NY, USA

M. J. Murphy, Jr.
Hipple Cancer Research Center, Dayton, OH, USA

R. Narayanan
Department of Biological Sciences, Florida Atlantic University, Boca Raton, FL, USA

K. Nilsson
Rudbeck Laboratory, Department of Genetics and Pathology, Uppsala University Hospital, Sweden

J. F. Novak
Department of Biology, Bucknell University, Lewisburg, PA, USA

S. Pathak
Department of Cell Biology, University of Texas, Houston, TX, USA

S. Pestka
Department of Molecular Genetics and Microbiology, University of Medicine and Dentistry of New Jersey, Piscataway, NJ, USA

G. J. Pilkington
Department of Cellular and Molecules Neurooncology, School of Pharmacy and Biomedical Sciences, University of Portsmouth, UK

C. D. Platsoucas
College of Sciences, Old Dominion University, Norfolk, VA, USA

F. Podo
Laboratory of Cell Biology, Istituto Superione di Sanità, Rome, Italy

continued
<table>
<thead>
<tr>
<th>Name</th>
<th>Institution and Cities</th>
</tr>
</thead>
<tbody>
<tr>
<td>A. Polliack</td>
<td>Department of Haematology, Hadassah University Hospital and Medical School, Jerusalem, Israel</td>
</tr>
<tr>
<td>M. F. Rajewsky</td>
<td>Institute of Cell Biology, University of Essen Medical School, Essen, Germany</td>
</tr>
<tr>
<td>G. Rebel</td>
<td>IRCAD, Hopitaux Universitaires, Strasbourg, France</td>
</tr>
<tr>
<td>M. Rigaud</td>
<td>Laboratory Biochimie et Génétique Molecules, Faculté de Médecine de Limoges, France</td>
</tr>
<tr>
<td>U. Ringborg</td>
<td>Department of General Oncology, Karolinska Hospital, Stockholm, Sweden</td>
</tr>
<tr>
<td>M. Roselli</td>
<td>Department of Medical Oncology, University of Rome “Tor Vergata”, Italy</td>
</tr>
<tr>
<td>A. Schauer</td>
<td>Zentrum Pathologie, Georg-August Universität, Göttingen, Germany</td>
</tr>
<tr>
<td>M. Schneider</td>
<td>Department of Organic Chemistry, Bergische University, Wuppertal, Germany</td>
</tr>
<tr>
<td>A. Seth</td>
<td>Laboratory of Molecular Pathology, Sunnybrook Research Institute and University of Toronto, Ontario, Canada</td>
</tr>
<tr>
<td>G. V. Sherbet</td>
<td>Cancer Research Unit, University of Newcastle-upon-Tyne, UK</td>
</tr>
<tr>
<td>G.-I. Soma</td>
<td>Institute for Health Sciences, Tokushima Bunri University, Tokushima, Japan</td>
</tr>
<tr>
<td>G. S. Stein</td>
<td>Department of Biochemistry, College of Medicine, University of Vermont, Burlington, VT, USA</td>
</tr>
<tr>
<td>T. Stigbrand</td>
<td>Department of Immunology, Umeå University, Umeå, Sweden</td>
</tr>
<tr>
<td>D. Tarin</td>
<td>University of California at San Diego, Cancer Center, La Jolla, CA, USA</td>
</tr>
<tr>
<td>T. M. Theophanides</td>
<td>Department of Chemistry, Technical University of Athens, Greece</td>
</tr>
<tr>
<td>B. Toth</td>
<td>The Eppley Institute for Research in Cancer and Allied Diseases, Omaha, NE, USA</td>
</tr>
<tr>
<td>P. M. Ueland</td>
<td>Clinical Pharmacology Unit, Department of Pharmacology, University of Bergen, Norway</td>
</tr>
<tr>
<td>P. T. Vihko</td>
<td>Department of Clinical Chemistry, University of Oulu, Finland</td>
</tr>
<tr>
<td>R.G. Vile</td>
<td>Department of Immunology, Mayo Clinic, Rochester, MN, USA</td>
</tr>
<tr>
<td>M. Volm</td>
<td>German Cancer Research Center, Heidelberg, Germany</td>
</tr>
<tr>
<td>G. Weber</td>
<td>Laboratory of Experimental Oncology, Indiana University, Indianapolis, IN, USA</td>
</tr>
<tr>
<td>B. Westermark</td>
<td>Rudbecklaboratoriet, Department of Genetics and Pathology, University of Uppsala, Sweden</td>
</tr>
<tr>
<td>Y. Yen</td>
<td>Department of Molecular Pharmacology, City of Hope, Duarte, CA, USA</td>
</tr>
<tr>
<td>B. Zumoff</td>
<td>Division of Endocrinology and Metabolism, Beth Israel Medical Center, New York, NY, USA</td>
</tr>
</tbody>
</table>

**ANTICANCER RESEARCH 33: (2013)**
Reviews